Planned Solutions Inc. Takes Position in Amgen Inc. (NASDAQ:AMGN)

Planned Solutions Inc. bought a new position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 104 shares of the medical research company’s stock, valued at approximately $30,000.

Other large investors have also added to or reduced their stakes in the company. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Amgen by 1.7% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after buying an additional 193 shares during the last quarter. Diversified Trust Co boosted its holdings in shares of Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after acquiring an additional 16,376 shares during the period. Nicolet Advisory Services LLC grew its position in shares of Amgen by 4.4% in the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares during the last quarter. Platform Technology Partners increased its stake in shares of Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock worth $1,567,000 after purchasing an additional 402 shares during the period. Finally, Busey Trust CO lifted its holdings in Amgen by 1.2% during the 3rd quarter. Busey Trust CO now owns 76,703 shares of the medical research company’s stock worth $20,615,000 after purchasing an additional 894 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AMGN. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Raymond James began coverage on shares of Amgen in a report on Thursday. They issued a “market perform” rating for the company. Oppenheimer reiterated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Morgan Stanley reduced their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada upped their target price on Amgen from $303.00 to $329.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus target price of $295.30.

Check Out Our Latest Report on Amgen

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $284.32 on Friday. The firm has a 50 day simple moving average of $289.68 and a 200 day simple moving average of $280.72. The company has a market cap of $152.37 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.70 and a beta of 0.58. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGNGet Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter in the prior year, the firm earned $4.09 EPS. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. Research analysts predict that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.